GLP-3
Recommended Dosage
Common wellness/research protocol: Start with 1–2 mg subcutaneously once weekly for the first 4 weeks (titration phase). Increase every 4 weeks as tolerated: 4 mg, then 8 mg, up to a maintenance dose of 8–12 mg once weekly. Lower starting doses (e.g., 0.5–2 mg) and slower escalation improve tolerability.
Other reported ranges: Maintenance doses in trials range from 4 mg to 12 mg weekly, with 8–12 mg associated with the strongest effects. Injections are given on the same day each week. Titration typically spans 12–16 weeks to reach target dose.
Reconstitution example (for typical research vials, e.g., 10–20 mg): Add 2 mL bacteriostatic water (yielding 5–10 mg/mL depending on vial size). Use an insulin syringe and calculate volume precisely for the target dose (e.g., at 10 mg/mL: 1 mg = 0.1 mL / 10 units; 4 mg = 0.4 mL / 40 units). Subcutaneous injection (abdomen, thigh, or upper arm) is the standard route.
Dosing is highly individualized based on goals (weight loss, glycemic control, metabolic support), tolerance, body weight, and response—consult a qualified healthcare provider experienced with incretin therapies for personalized guidance and monitoring. This is for informational purposes only.
Key Potential Benefits of Retatrutide
Triple Receptor Activation for Superior Appetite Control
Simultaneously activates GLP-1, GIP, and glucagon receptors, providing synergistic suppression of hunger and strong enhancement of satiety signals in the brain.
Dramatically reduces food cravings, emotional eating, and overall caloric intake through multiple complementary hormonal pathways.
Delivers more potent and sustained fullness compared to dual or single incretin agonists.
Unprecedented Weight Loss and Fat Reduction
Produces dose-dependent body weight reductions of up to ~24% at 48 weeks (and higher in some Phase 3 data) in clinical trials, setting new benchmarks for pharmacological weight loss.
Targets visceral and abdominal fat effectively while supporting overall fat mass reduction through combined appetite suppression and increased energy expenditure.
Promotes substantial improvements in body composition, waist circumference, and fat distribution.
Enhanced Glycemic Control and Metabolic Health
Improves insulin secretion in a glucose-dependent manner, suppresses glucagon, and slows gastric emptying for excellent blood sugar regulation.
Significantly lowers HbA1c, fasting glucose, and insulin levels while improving insulin sensitivity.
Supports favorable changes in lipid profiles, blood pressure, and inflammatory markers for broad cardiometabolic benefits.
Increased Energy Expenditure and Fat Metabolism
Glucagon receptor activation boosts resting metabolic rate, thermogenesis, and lipolysis, helping the body burn more calories even at rest.
Enhances fat oxidation and energy utilization, contributing to greater weight loss beyond appetite suppression alone.
Aids in efficient nutrient handling and metabolic flexibility during calorie restriction.
Liver Fat Reduction and Organ Protection
Achieves dramatic reductions in liver fat (up to 80–86% in participants with MASLD), with many reaching normal levels (<5%).
Supports improvements in liver enzymes, insulin sensitivity, and overall cardiometabolic risk factors.
Offers protective effects on the heart, kidneys, and other organs through comprehensive metabolic optimization.
Broader Wellness and Long-Term Resilience
Improves quality of life, physical function, and energy levels through significant weight loss and better metabolic health.
May provide additional benefits such as reduced osteoarthritis pain and enhanced daily vitality.
Supports sustainable long-term weight management and physiological resilience as part of a comprehensive approach.
Retatrutide is a first-in-class triple agonist (GLP-1/GIP/glucagon) designed for obesity and type 2 diabetes, offering additive benefits from all three pathways.
